Russell Investments Group Ltd. lifted its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 208.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 618,775 shares of the medical equipment provider’s stock after buying an additional 417,978 shares during the quarter. Russell Investments Group Ltd. owned about 1.62% of Lantheus worth $9,004,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $21,246,000. Factorial Partners LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $886,000. Boston Partners grew its position in shares of Lantheus by 198.1% during the 2nd quarter. Boston Partners now owns 356,790 shares of the medical equipment provider’s stock worth $5,191,000 after buying an additional 237,090 shares during the period. Piedmont Investment Advisors LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $104,000. Finally, Granite Investment Partners LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $706,000. Institutional investors own 92.63% of the company’s stock.
Several equities research analysts have recently commented on LNTH shares. BidaskClub upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Wednesday. ValuEngine upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Lantheus from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 4th. Credit Suisse Group decreased their price objective on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, August 2nd. Finally, Wells Fargo & Co decreased their price objective on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $23.75.
In related news, Director Julie Mchugh sold 4,560 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $14.72, for a total transaction of $67,123.20. Following the completion of the transaction, the director now owns 14,752 shares in the company, valued at $217,149.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.
Shares of NASDAQ LNTH opened at $15.40 on Friday. The company has a market cap of $589.82 million, a P/E ratio of 15.40, a PEG ratio of 3.54 and a beta of 1.30. The company has a quick ratio of 3.14, a current ratio of 3.86 and a debt-to-equity ratio of 5.94. Lantheus Holdings Inc has a 52-week low of $12.80 and a 52-week high of $24.45.
Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. The firm had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.35 earnings per share. equities research analysts predict that Lantheus Holdings Inc will post 0.87 earnings per share for the current year.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Featured Story: Short Selling Stocks, A Beginner’s Guide
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.